Kythera Pharmaceuticals (NASDAQ:KYTH) is a very interesting pharmaceutical company. Kythera has been able to attract a large pharmaceutical partner to its main product and has the potential to substantially reward long-term oriented investors. Kythera has only one main drug in its development pipeline, however, if approved the drug has the potential to significantly boost revenue and lead to increased shareholder value.
ATX-101 is the only meaningful product currently under development in Kythera's pipeline. With that said, the product has many important upcoming catalysts which have the potential to drive significant shareholder growth. ATX-101 is being developed for the reduction of submental fat. ATX-101 if approved would be the first drug approved in this segment, which would allow...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|